Mural Oncology PLC Logo

Mural Oncology PLC

Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.

MURA | BUD

Overview

Corporate Details

ISIN(s):
IE000LK2BOB4
LEI:
Country:
Ireland
Address:
N/A
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Mural Oncology PLC is a clinical-stage oncology company focused on developing novel immunotherapies to treat cancer. The company leverages its proprietary protein engineering platform and expertise in cytokine biology to design and advance a pipeline of cytokine-based therapies. Its mission is to unlock the value of immunotherapy for a broader range of patients, particularly those with cancers that have not responded to previous treatments. The company's lead candidate, nemvaleukin alfa, is a novel, engineered interleukin-2 (IL-2) variant immunotherapy currently in clinical trials for difficult-to-treat solid tumors, including advanced melanoma and platinum-resistant ovarian cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-24 22:25
Post-Annual General Meeting Information
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisiti…
English 31.3 KB
2025-09-24 01:52
Proxy Solicitation & Information Statement
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement …
English 18.3 KB

Automate Your Workflow. Get a real-time feed of all Mural Oncology PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mural Oncology PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mural Oncology PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan
4587

Talk to a Data Expert

Have a question? We'll get back to you promptly.